Alcidion Group Ltd (ASX: ALC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alcidion Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$387.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
1.05 billion
Earnings per share
-0.003
Dividend per share
N/A
Year To Date Return
100.00%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alcidion Group Ltd (ASX: ALC)
Latest News
Small Cap Shares
2 small cap ASX shares that this broker rates as buys
Share Gainers
Alcidion (ASX:ALC) share price jumps 14% on solid earnings
Ask a Fund Manager
‘That hurts’: Fund manager reveals his 35-bagger ‘failure’
Small Cap Shares
3 growing small cap ASX shares to watch
Small Cap Shares
4 fast-growing ASX small cap shares that you may have overlooked
Small Cap Shares
4 exciting small cap ASX shares to watch
Technology Shares
Why has the Alcidion (ASX:ALC) share price rocketed 20% in the last month?
Small Cap Shares
3 exciting small cap ASX shares to watch
ALC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alcidion Group Ltd
Alcidion Group Ltd (ASX: ALC) is a Melbourne-based company focused on developing and licensing a range of software products for use in the healthcare sector. The company’s own brands include Miya, Patientrack and Smartpage and it also distributes selected products developed by its partner organisations.
Alcidion has offices and operations throughout Australia as well as in New Zealand and the United Kingdom. Its technology platforms are designed to improve the accuracy, efficiency and functionality of the often myriad of disconnected IT systems used in healthcare environments. As at October 2020, the company’s platforms are utilised by more than 65,000 users across over 300 hospitals in Australia, New Zealand and the UK.
According to Alcidion, the company is committed to continually innovating in its quest to support clinicians and improve the management and workflow of healthcare operations. Alcidion first listed on the ASX in mid-2011. The Alcidion share price has not been an overly strong performer and, despite reaching as high as 30 cents in late 2019, has spent much of the time since listing trading around or below 10 cents.
ALC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Aug 2021 | $0.37 | $0.00 | 0.00% | 988,756 | $0.37 | $0.38 | $0.37 |
| 02 Aug 2021 | $0.37 | $-0.01 | -2.63% | 617,293 | $0.38 | $0.38 | $0.37 |
| 30 Jul 2021 | $0.38 | $0.01 | 2.67% | 902,078 | $0.39 | $0.39 | $0.38 |
| 29 Jul 2021 | $0.38 | $-0.02 | -5.06% | 1,487,481 | $0.39 | $0.40 | $0.38 |
| 28 Jul 2021 | $0.40 | $-0.01 | -2.47% | 2,109,767 | $0.40 | $0.40 | $0.39 |
| 27 Jul 2021 | $0.41 | $0.05 | 14.08% | 4,966,933 | $0.37 | $0.42 | $0.37 |
| 26 Jul 2021 | $0.36 | $-0.01 | -2.78% | 928,749 | $0.37 | $0.37 | $0.36 |
| 23 Jul 2021 | $0.36 | $-0.02 | -5.26% | 1,081,546 | $0.38 | $0.38 | $0.36 |
| 22 Jul 2021 | $0.38 | $0.02 | 5.48% | 956,662 | $0.37 | $0.38 | $0.36 |
| 21 Jul 2021 | $0.37 | $0.01 | 2.82% | 980,803 | $0.36 | $0.37 | $0.36 |
| 20 Jul 2021 | $0.36 | $-0.01 | -2.78% | 1,523,614 | $0.36 | $0.36 | $0.35 |
| 19 Jul 2021 | $0.36 | $-0.02 | -5.33% | 1,769,998 | $0.37 | $0.37 | $0.36 |
| 16 Jul 2021 | $0.38 | $-0.02 | -5.13% | 588,404 | $0.39 | $0.39 | $0.38 |
| 15 Jul 2021 | $0.39 | $-0.01 | -2.53% | 968,952 | $0.40 | $0.40 | $0.38 |
| 14 Jul 2021 | $0.40 | $0.00 | 0.00% | 1,342,143 | $0.40 | $0.40 | $0.38 |
| 13 Jul 2021 | $0.40 | $0.01 | 2.60% | 1,013,265 | $0.38 | $0.40 | $0.38 |
| 12 Jul 2021 | $0.39 | $0.03 | 8.33% | 1,918,239 | $0.36 | $0.39 | $0.36 |
| 09 Jul 2021 | $0.36 | $-0.01 | -2.74% | 1,515,546 | $0.37 | $0.37 | $0.36 |
| 08 Jul 2021 | $0.37 | $-0.01 | -2.67% | 1,243,495 | $0.38 | $0.38 | $0.37 |
| 07 Jul 2021 | $0.38 | $0.00 | 0.00% | 2,662,304 | $0.38 | $0.38 | $0.37 |
| 06 Jul 2021 | $0.38 | $-0.01 | -2.60% | 1,015,517 | $0.38 | $0.39 | $0.37 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 May 2021 | Simon Chamberlain | Buy | 295 | $100,300 |
On-market trade.
|
| 17 May 2021 | Katrina (Kate) Doyle (Quirke) | Sell | 11 | $3,903,632 |
On-market trade. As per announcement on 18/05/2021.
|
| 11 May 2021 | Rebecca Wilson | Issued | 22 | $7,231 |
Participation in share purchase plan.
|
| 11 May 2021 | Rebecca Wilson | Issued | 15 | $4,904 |
Participation in share purchase plan.
|
| 11 May 2021 | Raymond Blight | Issued | 93 | $30,000 |
Participation in share purchase plan.
|
| 20 Nov 2020 | Malcolm Pradhan | Issued | 563 | $107,028 |
Issue of securities. 563,309 - Performance Rights
|
| 20 Nov 2020 | Katrina (Kate) Doyle (Quirke) | Issued | 2 | $484,027 |
Issue of securities. 2,547,511 - Performance Rights
|
| 28 Sep 2020 | Katrina (Kate) Doyle (Quirke) | Buy | 1 | $195,000 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Wilson | Non-Executive DirectorNon-Executive Chairman | Jul 2017 |
Ms Wilson has more than 20 years' experience working within the healthcare, technology and life science sectors providing advice on stakeholder communications, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She advises boards and executive teams on investor relations and commercial strategies and has strong experience in transactions, including more than 60 IPOs, M&A transactions, and hundreds of capital raisings. Rebecca is Executive Vice President Singapore & Australia for WE Communications, Executive Director of consulting firm WE Buchan, and Advisory Board member of Gillian Fox Leadership.
|
| Mr Simon Chamberlain | Non-Executive Director | Jul 2019 |
Mr Chamberlain is an executive and business leader, with more than 20 years' experience at companies including Medibank Private, Qantas Airways, Australian Unity and Experian. Simon has a track record for strategic and commercial growth across a range of industries and markets. Simon led Qantas' entrance into the online hotels business. At Medibank, Simon had responsibility across all customer channels and the enterprise's data and oversaw the creation of its customer experience practice. He led role for MedAdvisor.
|
| Mr Nicholas Paul Dignam | Non-Executive Director | Feb 2016 |
Mr Dignam is a Partner of Fortitude Investment Partners. Nick has more than ten years' experience working in private equity. Nick also serves as a director on the Board of a number of Fortitude's portfolio companies including Better Medical, Birch & Waite, Sunfresh Salads, Wild Breads and GM Hotels. Nick has previously served on the Boards of HPS and Readify. Prior to establishing Fortitude, Nick was the Head of Growth Capital in Blue Sky's Private Equity division, and prior to this he was an investment director with Catalyst Investment Managers. Before Catalyst Nick spent three years with Ernst & Young in the corporate finance division.
|
| Professor Malcolm Pradhan | Executive Director | Feb 2016 |
Professor Pradhan has over 25 years of experience in Medical Informatics. Malcolm was as a founding fellow of the Australasian College of Health Informatics (ACHI).Throughout his career, Malcolm has been a advocate for interoperability, and a sustainable health care system using smart data-driven IT systems that improve patient safety, reduce clinician workloads and support new models of care.
|
| Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Ms Quirke has more than 25 years of experience in the healthcare information technology sector. She has been involved in systems procurements and implementations of healthcare information technology across Australia, New Zealand and South East Asia. Kate's background involves holding management roles at some of the healthcare software firms.
|
| Ms Melanie Jaye Leydin | Company Secretary | Mar 2019 |
-
|
| Melanie Jaye Leydin | Company Secretary |
-
|
|
| Colin MacKinnon | Group Commercial Manager Chief Operating Officer Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malcolm Pradhan | 134,582,403 | 13.58% |
| Mr Raymond Blight | 95,828,781 | 9.67% |
| Isle of Wight Pty Limited | 49,405,192 | 4.99% |
| Caledonia Nominees Pty Limited | 49,221,085 | 4.97% |
| 1P Morgan Nominees Australia Pty Limited | 36,720,940 | 3.71% |
| Mrs Katrina Doyle | 27,793,199 | 2.81% |
| Rangiora-London Pty Limited | 26,602,251 | 2.69% |
| Rewmicman Pty Limited | 26,026,606 | 2.63% |
| MNMD Pty Limited | 17,168,086 | 1.73% |
| HSBC Custody Nominees (Australia) Limited | 15,449,926 | 1.56% |
| MKMS Investment Pty Limited | 11,481,273 | 1.16% |
| Mr Colin MacKinnon & Mrs Mares MacKinnon | 9,676,550 | 0.98% |
| Citicorp Nominees Pty Limited | 8,124,310 | 0.82% |
| Mr Michael Buist & MRS Sarah Buist | 8,010,280 | 0.81% |
| Rewmicman Pty Limited (I) | 7,533,835 | 0.76% |
| The Andromeda Group Pty Limited | 5,998,133 | 0.61% |
| Emerald Shares Pty Limited | 5,850,000 | 0.59% |
| Dr Michael Buist | 5,779,039 | 0.58% |
| JBWere (NZ) Nominees Limited | 5,734,603 | 0.58% |
| Mr Vivek Ramakrishnan & Miss Nisha Srinivasan | 5,186,789 | 0.52% |